Oral Inflammation
Conditions
Brief summary
The purpose of this multicenter, prospective, single arm Study is to evaluate the efficacy and safety of PerioMonitor as an aid to the detection of oral inflammation associated with periodontal diseases. PerioMonitor is an IVD device for the rapid, semi-quantitative detection of neutrophil enzyme activity in oral samples. This test is intended for prescription use at Point-of-Care (POC) settings by health care professionals.
Detailed description
The purpose of this multicenter, prospective, single arm Study is to evaluate the efficacy and safety of PerioMonitor as an aid to the detection of oral inflammation associated with periodontal diseases. PerioMonitor is an IVD device for the rapid, semi-quantitative detection of neutrophil enzyme activity in oral samples. This test is intended for prescription use at Point-of-Care (POC) settings by health care professionals. The primary objective of this Study is to evaluate the Positive Percent Agreement (PPA)PPA and the Negative Percent Agreement (NPA)NPA of PerioMonitor for semi-quantitative detection of neutrophil enzyme activity in human oral specimens, to detect oral inflammation associated with periodontal diseases (subjects having more than 50 000 neutrophils/mL in their oral specimen or having more than 10% of bleeding sites when tested with the BOP method). The secondary objective is to validate the claim that PerioMonitor can be used in POC settings (i.e., representative of the intended users and under conditions similar to the conditions of use), at the time of the consultation, with instant availability of results, by healthcare professionals (HCP) working in a dental clinic (i.e. with the background, education, and training of those who will perform the test in its intended environment) that are not qualified laboratory technicians, to make immediate and informed decisions about patient care.
Interventions
None listed
Sponsors
Advarra
Oral Science International Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* subject \> 18 years old; * subject fluent in English; and * subject has signed the ICF
Exclusion criteria
* Subject with altered mental status/inability to provide informed consent or follow the procedure of the Study; and * Subject using immunosuppressants including biologics such as adalimumab (Humira) and infliximab (Remicade); or calcineurin inhibitors such as tacrolimus (Envarsus XR or Protopic) and cyclosporine (Gengraf, Neotal or Sandimmmune); or corticosteroids (Prednisone); or azathioprine (Imuran) * Oral rinse specimens received 5 days or more after PerioMonitor testing by the clinical laboratory * Previous enrolment into the current Study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding on Probing (BOP) | 6 months | Confirmation of oral inflammation if BOP is equal or above 10% |
Contacts
Primary ContactMichel Houde, Ph.D.
Backup ContactJulie Struthers, B.Sc
Outcome results
None listed